Quintiles has been named the market leader in Phase IV services for the third year in a row. That’s according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers Report from Industry Standard Research (ISR).

Quintiles was selected as the preferred provider among biopharmaceutical companies for Phase IV services based on a survey of 110 global biopharmaceutical representatives. Phave IV monitored are aimed at addressing drug product success after regulartory approval.

Quintiles was highlighted as a leader across a number of key service quality metrics, including its service breadth, global footprint and technology that enables real-time data access delivered by its award-winning Quintiles Infosario® platform.

Top performer in these categories

Compared to the other 33 Phase IV Contract Research Organizations noted in the report, Quintiles was a top performer in a number of selection criteria including:

  • ·         Leadership
  • ·         Preference
  • ·         Customer loyalty
  • ·         Performance relative to expectations
  • ·         Perceived differentiation of service quality

Survey participants were decision-makers from small, mid-size and large global biopharmaceutical companies and were required to have been involved in outsourced Phase IV trials within the past 18 months.

To learn more about the report see: http://www.isrreports.com/reports/cro-quality-benchmarking-phase-iv-service-providers-7th-edition/